Rating Change
JP Morgan analysts initiated coverage on Tango Therapeutics, Inc. (NASDAQ:TNGX) with a Overweight rating on July 15, 2026.
Rating Change JP Morgan analysts initiated coverage on Tango Therapeutics, Inc. (NASDAQ:TNGX) with a Overweight rating on July 15, 2026. Market Context Tango Therapeutics, Inc.

JP Morgan analysts initiated coverage on Tango Therapeutics, Inc. (NASDAQ:TNGX) with a Overweight rating on July 15, 2026.
Tango Therapeutics, Inc. operates in the Healthcare sector. The stock currently trades at $30.25 with a market capitalization of $1.0B. The stock has gained 400.0% over the past 52 weeks.
Analyst coverage from JP Morgan provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Tango Therapeutics, Inc..
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Among the 10 most recent ratings: 8 Buy, 2 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Jul 15, 2026 | JP Morgan | Overweight | N/A |
| Jun 29, 2026 | Canaccord Genuity | Buy | N/A |
| Jun 26, 2026 | Jefferies | Buy | N/A |
| Jun 11, 2026 | Canaccord Genuity | Buy | N/A |
| Jun 09, 2026 | HC Wainwright & Co. | Buy | N/A |
Related Tools: Analyst Ratings Dashboard | View TNGX Stock Page
A Overweight rating from JP Morgan reflects the analyst's outlook on Tango Therapeutics, Inc. (NASDAQ:TNGX). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the TNGX forecast page.
Current market data
NASDAQ · TNGX
$23.37
Up: +$0.16 · +0.68%
Live quote updated
Keep reading
analyst ·
analyst ·
sec_filing ·
earnings ·